AI Article Synopsis

  • A synthetic gene for a part of botulinum neurotoxin serotype A was created and successfully expressed in E. coli, producing the protein fragment that was tested.
  • Mice vaccinated with the E. coli extracts showed strong immunity, surviving high doses of both botulinum serotype A and E toxins, highlighting the vaccine's effectiveness.
  • Purified fragment C proved to be as protective as a traditional toxoid vaccine, suggesting its potential for human use against botulinum toxin.

Article Abstract

A completely synthetic gene encoding fragment C, a approximately 50-kDa fragment, of botulinum neurotoxin serotype A was constructed from oligonucleotides. The gene was expressed in Escherichia coli, and full-sized product was produced as judged by Western blot (immunoblot) analysis. Crude extracts of E. coli expressing the gene were used to vaccinate mice and evaluate their survival against challenge with active toxin. Mice given three subcutaneous vaccinations were protected against an intraperitoneal administration of 10(6) 50% lethal doses (ID50) of serotype A toxin. The same mice survived when challenged with 3 LD50 of botulinum toxin serotype E but died when challenged with 10 LD50 of serotype E or 3 LD50 of serotype B. Purified fragment C was compared with the botulinum toxoid vaccine in a vaccination and challenge study. Fragment C was as efficacious in protecting against challenge with active botulinum neurotoxin serotype A as the toxoid vaccine. This recombinant protein product has many properties that make it a good candidate for human use to protect against botulinum toxin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC173366PMC
http://dx.doi.org/10.1128/iai.63.7.2738-2742.1995DOI Listing

Publication Analysis

Top Keywords

botulinum neurotoxin
12
neurotoxin serotype
12
synthetic gene
8
escherichia coli
8
challenge active
8
toxin mice
8
challenged ld50
8
botulinum toxin
8
ld50 serotype
8
toxoid vaccine
8

Similar Publications

Botulinum toxin injections, a popular aesthetic treatment, have over 7.4 million beneficiaries in the U.S.

View Article and Find Full Text PDF

BoNT/Action beyond neurons.

Toxicon

January 2025

National Research Council of Italy, Institute of Biochemistry and Cell Biology, 00015, Monterotondo, RM, Italy. Electronic address:

Botulinum neurotoxin type A (BoNT/A) has expanded its therapeutic uses beyond neuromuscular disorders to include treatments for various pain syndromes and neurological conditions. Originally recognized for blocking acetylcholine release at neuromuscular junctions, BoNT/A's effects extend to both peripheral and central nervous systems. Its ability to undergo retrograde transport allows BoNT/A to modulate synaptic transmission and reduce pain centrally, influencing neurotransmitter systems beyond muscle control.

View Article and Find Full Text PDF

Repetitive intramuscular injections of botulinum neurotoxin (BoNT) have become the treatment of choice for a variety of disease entities. But with the onset of BoNT therapy, the natural course of a disease is obscured. Nevertheless, the present study tries to analyze patients' "suspected" course of disease severity under the assumption that no BoNT therapy had been performed and compares that with the "experienced" improvement during BoNT treatment.

View Article and Find Full Text PDF

Botulinum toxin (BoNT), the most potent substance known to humans, likely evolved not to kill but to serve other biological purposes. While its use in cosmetic applications is well known, its medical utility has become increasingly significant due to the intricacies of its structure and function. The toxin's structural complexity enables it to target specific cellular processes with remarkable precision, making it an invaluable tool in both basic and applied biomedical research.

View Article and Find Full Text PDF

Background: Botulinum toxin is an attenuated neurotoxin of Clostridium Botulinum gram positive bacterial, which is used in medication sialorrhea, cervical dystonia, hyperhidrosis and non-surgical cosmetic operation (aesthetic) such as facial wrinkles and reduced the bulky appearance hypertrophied of masseter muscle. This study was designed to revealed the effect of zygomiticus inoculation of botulinum toxin B in zygomatic muscle of rats on zygomatic bone.

Methods: A total of 25 male albino rats (200-260 gm) were injected facial intramuscular by a single dose of 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!